Marshall Wace North America’s Ionis Pharmaceuticals IONS Stock Holding History

Marshall Wace North America’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-42,512	Closed	-$2.02M	–	1430
2020 Q3	$2.02M	Buy	+42,512	New	+$2.36M	0.01%	591
2020 Q1	–	Sell	-3,939	Closed	-$238K	–	1407
2019 Q4	$238K	Sell	3,939 -111,832	-97%	-$6.66M	﹤0.01%	937
2019 Q3	$6.94M	Buy	+115,771	New	+$7.55M	0.04%	307
2018 Q2	–	Sell	-173,750	Closed	-$7.66M	–	1527
2018 Q1	$7.66M	Buy	173,750 +41,117	+31%	+$2.09M	0.04%	464
2017 Q4	$6.67M	Buy	132,633 +48,046	+57%	+$2.63M	0.04%	493
2017 Q3	$4.31M	Buy	+84,587	New	+$4.43M	0.03%	587

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Marshall Wace North America's IONS Position: Q4 2020 in Review

Marshall Wace North America sold out of Ionis Pharmaceuticals (IONS) in Q4 2020, closing a stake of 42,512 shares — an estimated $2.02M sold.

Marshall Wace North America first reported a position in IONS in Q3 2017 and held it in 6 quarters. The position peaked at $7.66M in Q1 2018. 382 funds tracked by Wall St. Rank hold IONS as of Q4 2020.

Marshall Wace North America reported no remaining Ionis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 42,512 Ionis Pharmaceuticals shares in Q4 2020, an estimated $2.02M.
Marshall Wace North America first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Marshall Wace North America's Ionis Pharmaceuticals position peaked at $7.66M in Q1 2018.
382 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.